Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) received FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System. The clearance covers instrument upgrades and reclassification of select tools from disposable to reusable, intended to lower per-procedure costs and support gross margin and cash flow.
The Catamaran system uses a single titanium implant via a minimally invasive, inferior-posterior SI joint approach. Since its October 2022 U.S. launch, over 1,500 Catamaran Fixation Devices have been implanted.
Tenon Medical (NASDAQ:TNON) closed a public offering totaling $4.2 million in gross proceeds. The deal included 11,052,631 common shares (or pre-funded warrants) plus common warrants for up to 13,263,159 shares at a combined price of $0.38 per share and warrant.
Proceeds are earmarked for partial repayment of convertible notes, commercial expansion, clinical research, R&D and product launches, inventory and instrumentation, marketing, working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON) closed a public offering for approximately $4.2 million in gross proceeds. The deal included 11,052,631 common shares (or pre-funded warrants) plus Common Warrants for up to 13,263,159 shares at a combined price of $0.38 per share.
Proceeds are expected to fund partial repayment of convertible notes, commercial expansion, clinician training, added sales reps and distributors, clinical research, R&D for future launches, higher inventory and instrumentation, marketing, working capital and general corporate purposes. Common and pre-funded warrants are immediately exercisable.
Tenon Medical (NASDAQ:TNON) priced a registered public offering for approximately $4.2 million in gross proceeds. The deal includes up to 11,052,631 shares (or pre-funded warrants) plus 13,263,159 common warrants at a combined public price of $0.38 per share and warrant.
According to Tenon, net proceeds will fund partial repayment of convertible notes, commercial expansion, clinical research, R&D for future product launches, inventory and instrumentation, marketing, working capital and general corporate purposes. Common and pre-funded warrants are immediately exercisable.
Tenon Medical (NASDAQ:TNON) priced a public offering for approximately $4.2 million in gross proceeds. The deal includes up to 11,052,631 shares of common stock (or pre-funded warrants) plus Common Warrants to purchase up to 13,263,159 shares at a combined price of $0.38.
According to Tenon Medical, net proceeds will fund partial repayment of convertible notes, commercial expansion, clinical research, R&D and product launches, inventory and instrumentation, marketing, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) reported first quarter 2026 revenue of $1.4 million, up about 90% year-over-year, with gross profit of $0.9 million and gross margin expanding to 68.5%.
The company posted a net loss of $3.5 million, closed a $4.3 million senior convertible note financing, and expanded its IP, training, and commercial footprint.
Tenon Medical (NASDAQ:TNON) will release first quarter 2026 financial results for the period ended March 31, 2026 after market close on Tuesday, May 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time the same day with a Q&A session.
Dial-in numbers, international access, a webcast, and an audio replay available through May 26, 2026 are provided; the telephone replay access code is 13759830.
Tenon Medical (NASDAQ:TNON) reported record Q4 2025 revenue of $1.5M (up 92% YoY) and record full-year 2025 revenue of $3.9M (up 20% YoY). Gross profit was $1.0M in Q4 and $2.4M for 2025, with margins improving to 69% and 60% respectively.
The company secured FDA 510(k) clearance for SImmetry+ and completed initial procedures, closed a $2.85M ATM PIPE in Q4, and announced a subsequent $4.3M senior convertible note placement in March 2026.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior original-issue-discount convertible notes, raising $4.3 million aggregate gross proceeds.
The 20% OID notes mature on September 11, 2026 and are convertible after six months into common stock at a conversion price equal to 80% of the 3-day VWAP prior to conversion. Net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior convertible notes for $4.3 million gross on March 12, 2026. The notes carry a 20% original issue discount, mature on September 11, 2026, and convert after six months at 80% of the 3‑day VWAP.
The company said net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes. Placement agent fees apply; notes and conversion shares are unregistered.